Consorcio Hospital General Universitario De Valencia — Clinical Trial Site

10 Registered trials

5 Currently recruiting

Organisation

Consorcio Hospital General Universitario De Valencia

Location

Castello De La Plana, Spain

Identifier

ORG-100028968

Address

Provincial De Castellon, Avinguda Del Doctor Clara 19, 12006, Spain

Departments

2404:Servicio Dermatología
Hepatology Unit
Medical Oncology
Oncología
Oncología Médica
Oncology
Servicio de Oncologia médica

Clinical trials at this site (10)

Search interface

A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting

2024-510778-26-00 Metastatic Non-Small-Cell Lung Cancer 4 2025-12-19
Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tum… Recruiting

2024-518131-11-02 Localised Colon Cancer (stage II-III) 4 2025-01-24
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Head and Neck Squamous Cell Carcinoma (HNSCC) 5 2024-10-15
24 weeks double-blind randomized placebo-controlled trial to evaluate efficacy, PK, safety of LOU064 in adolescents (12 - <18) with CSU and … Recruiting

2022-502159-78-00 Chronic Spontaneous Urticaria 5 2023-12-06
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
PLUG-IN. Phase 2 of pembrolizumab combined with enfortumab vedotin for advanced melanoma patients. Ended

2024-514163-26-00 Advanced Melanoma 4 2025-06-09
A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr… Ended

2023-508248-23-00 Non-alcoholic steatohepatitis (NASH) 5 2021-11-26
Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit… Ended

2024-512243-23-00 gastrointestinal stromal tumor 5 2014-11-07
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 HR-positive/HER2-negative breast cancer 4 2021-05-04
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended

2023-505035-12-00 RET fusion−positive, metastatic Non-Small Cell Lung Can 5 2020-06-12